Government of Canada announces funding for advancements in mRNA vaccine technology at UBC

Funding of $11.1 million for two UBC projects to improve pathogen response and boost the impact of B.C. biotechnology on the global stage.

The Honourable Harjit S. Sajjan, Minister for International Development and Minister responsible for the Pacific Economic Development Agency of Canada (PacifiCan), announced over $11.1 million in funding through PacifiCan for the University of British Columbia (UBC) to undertake two new projects to enhance the delivery and efficacy of mRNA vaccines.

The two project teams will work in tandem, meeting regularly and coordinating research to maximize the value and effectiveness of both projects.

Improve the delivery technology behind mRNA vaccines and other nanomedicines

The University of British Columbia will acquire key equipment and enhance lab resources to improve vaccine delivery technology. In partnership with leading B.C. biotechnology companies, UBC aims to accelerate the development of vaccine delivery techniques for commercial application on a global scale.

Through analyzing how mRNA vaccines interact with cells and create defenses against pathogens, researchers will work to optimize the administration of those vaccines. Key objectives in this research project include minimizing any potential side effects, reducing the necessary vaccine dosage, and optimizing the potency of mRNA vaccines, among others.

This work will advance the development of future mRNA vaccines and other medicines. Expected economic benefits of this project include the creation of 70 new jobs, the training of 80 new highly qualified biotechnology professionals, and revenue growth of at least $90 million for the B.C. biotechnology sector.

Grow B.C. biotech by advancing in-vitro and in-situ antiviral therapy for SARS-CoV2 variants

This project will see UBC acquire key equipment and enhance lab operations to advance antiviral therapy for COVID-19 variants. This will involve identifying, testing and developing responses to existing COVID-19 variants and establishing a vaccine development framework in B.C.

Working closely with B.C. biotechnology companies, UBC will study the COVID-19 Delta variant at a molecular level and use AI predictive models to create mRNA vaccine treatments for potential future variants. Through this process, UBC and its partners will develop a pipeline for rapid anti-viral drug development, enabling a local response to new and emerging COVID-19 variants for worldwide commercial application.

Overall, this will allow B.C. to provide international leadership in vaccine research and raise the visibility of B.C. biotech within the global community. Expected economic benefits of this project include creating at least 170 jobs at UBC and industry partners, training 75 highly qualified personnel and growing revenue by at least $70 million for the B.C. biotechnology sector. 

"PacifiCan is committed to supporting British Columbia’s life sciences sector and these projects at the University of British Columbia reflect that commitment. Establishing a home-grown pipeline for mRNA vaccine research will not only save lives, but create jobs for British Columbians and position Canada as a global leader in biotechnology innovation.”
- The Honourable Harjit S. Sajjan, Minister of International Development and Minister responsible for the Pacific Economic Development Agency of Canada

“With cutting-edge research led by some of the brightest minds globally, UBC continues to excel in biotechnology and life sciences research and innovation. With the generous support of the Government of Canada through PacifiCan announced today, our researchers will be able to help development treatments for new COVID-19 variants and improve the efficacy of mRNA vaccines and other therapeutics for a wide range of diseases.”
- Santa J. Ono, President and Vice-Chancellor, University of British Columbia 

“UBC has long been a major driver of the B.C. biotech sector, but those connections and their outputs really gained international attention during the pandemic. AbCellera, Acuitas, and Precision Nanosystems, among many others, are now major players in the treatment and prevention of diseases. This funding builds off many years of collaboration between UBC and local biotech companies and will enable us to continue developing and refining vaccines, drugs, and biologics.”
- Dr. Leonard Foster, Professor, Department of Biochemistry and Molecular Biology, University of British Columbia

Read the media release

  • Stories
  • Partnerships

UBC Crest The official logo of the University of British Columbia. Urgent Message An exclamation mark in a speech bubble. Caret An arrowhead indicating direction. Arrow An arrow indicating direction. Arrow in Circle An arrow indicating direction. Arrow in Circle An arrow indicating direction. Chats Two speech clouds. Facebook The logo for the Facebook social media service. Information The letter 'i' in a circle. Instagram The logo for the Instagram social media service. External Link An arrow entering a square. Linkedin The logo for the LinkedIn social media service. Location Pin A map location pin. Mail An envelope. Menu Three horizontal lines indicating a menu. Minus A minus sign. Telephone An antique telephone. Plus A plus symbol indicating more or the ability to add. Search A magnifying glass. Twitter The logo for the Twitter social media service. Youtube The logo for the YouTube video sharing service.